A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 19, 2013

Primary Completion Date

May 18, 2017

Study Completion Date

May 18, 2017

Conditions

Advanced Malignancies

Interventions

DRUG

MEDI0680 (AMP-514)

Study has planned dose escalation cohorts

Trial Locations (6)

Research Site, The Bronx

Research Site, Nashville

Research Site, Detroit

Research Site, Houston

Research Site, Portland

Research Site, New Haven